Clinical Trial Update: Chidamide and PD-1 Inhibitor Plus Anlotinib for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update investigating chidamide together with a PD-1 inhibitor and anlotinib for HER2-low breast cancer that has spread or is unresectable…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Chidamide (chidamide)
• PD-1 inhibitor

Snippet

Sponsor: Guangdong Provincial People's Hospital | Conditions: Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING